Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Documenti analoghi

• Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children
  di: Robbie, Gabriel J., et al.
  Pubblicazione: (2012)
• Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
  di: Narwal, Rajesh, et al.
  Pubblicazione: (2013)
• Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab
  di: Zhu, Qing, et al.
  Pubblicazione: (2011)
• Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion
  di: Huang, Kelly, et al.
  Pubblicazione: (2010)
• Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
  di: Resch, Bernhard
  Pubblicazione: (2017)